Oncogenic Roles of the PI3K/AKT/mTOR Axis
- PMID: 28550454
- DOI: 10.1007/82_2017_6
Oncogenic Roles of the PI3K/AKT/mTOR Axis
Abstract
The PI3K/AKT/mTOR pathway is frequently activated in various human cancers and has been considered a promising therapeutic target. Many of the positive regulators of the PI3K/AKT/mTOR axis, including the catalytic (p110α) and regulatory (p85α), of class IA PI3K, AKT, RHEB, mTOR, and eIF4E, possess oncogenic potentials, as demonstrated by transformation assays in vitro and by genetically engineered mouse models in vivo. Genetic evidences also indicate their roles in malignancies induced by activation of the upstream oncoproteins including receptor tyrosine kinases and RAS and those induced by the loss of the negative regulators of the PI3K/AKT/mTOR pathway such as PTEN, TSC1/2, LKB1, and PIPP. Possible mechanisms by which the PI3K/AKT/mTOR axis contributes to oncogenic transformation include stimulation of proliferation, survival, metabolic reprogramming, and invasion/metastasis, as well as suppression of autophagy and senescence. These phenotypic changes are mediated by eIF4E-induced translation of a subset of mRNAs and by other downstream effectors of mTORC1 including S6K, HIF-1α, PGC-1α, SREBP, and ULK1 complex.
Keywords: Cancer; Genetically engineered mouse models; Oncogenic transformation; PI3K/AKT/mTOR pathway.
Similar articles
-
PI3K/AKT/mTOR Signaling Regulates the Virus/Host Cell Crosstalk in HPV-Positive Cervical Cancer Cells.Int J Mol Sci. 2019 May 3;20(9):2188. doi: 10.3390/ijms20092188. Int J Mol Sci. 2019. PMID: 31058807 Free PMC article. Review.
-
AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy.Oncogene. 2012 Apr 12;31(15):1949-62. doi: 10.1038/onc.2011.394. Epub 2011 Sep 12. Oncogene. 2012. PMID: 21909130 Free PMC article.
-
S6K Promotes Dopaminergic Neuronal Differentiation Through PI3K/Akt/mTOR-Dependent Signaling Pathways in Human Neural Stem Cells.Mol Neurobiol. 2016 Aug;53(6):3771-3782. doi: 10.1007/s12035-015-9325-9. Epub 2015 Jul 5. Mol Neurobiol. 2016. PMID: 26143260
-
The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.Gynecol Oncol. 2015 Apr;137(1):173-9. doi: 10.1016/j.ygyno.2015.02.003. Epub 2015 Feb 10. Gynecol Oncol. 2015. PMID: 25677064 Review.
-
Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.Cell Signal. 2014 Dec;26(12):2782-92. doi: 10.1016/j.cellsig.2014.08.021. Epub 2014 Sep 2. Cell Signal. 2014. PMID: 25193113
Cited by
-
Roles of oncogenes in esophageal squamous cell carcinoma and their therapeutic potentials.Clin Transl Oncol. 2023 Mar;25(3):578-591. doi: 10.1007/s12094-022-02981-x. Epub 2022 Oct 31. Clin Transl Oncol. 2023. PMID: 36315334 Review.
-
PTEN is recognized as a prognostic-related biomarker and inhibits proliferation and invasiveness of skull base chordoma cells.Front Surg. 2022 Sep 23;9:1011845. doi: 10.3389/fsurg.2022.1011845. eCollection 2022. Front Surg. 2022. PMID: 36211273 Free PMC article.
-
Posttranslational control of lipogenesis in the tumor microenvironment.J Hematol Oncol. 2022 Aug 29;15(1):120. doi: 10.1186/s13045-022-01340-1. J Hematol Oncol. 2022. PMID: 36038892 Free PMC article. Review.
-
Tenascin-C promotes epithelial-to-mesenchymal transition and the mTOR signaling pathway in nasopharyngeal carcinoma.Oncol Lett. 2021 Jul;22(1):570. doi: 10.3892/ol.2021.12831. Epub 2021 May 29. Oncol Lett. 2021. PMID: 34113398 Free PMC article.
-
Antinociceptive Effects of Shenling Baizhu through PI3K-Akt-mTOR Signaling Pathway in a Mouse Model of Bone Metastasis with Small-Cell Lung Cancer.Evid Based Complement Alternat Med. 2020 Jun 22;2020:4121483. doi: 10.1155/2020/4121483. eCollection 2020. Evid Based Complement Alternat Med. 2020. PMID: 32655659 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
